Royal Bank of Canada
AVDL

Royal Bank of Canada’s Avadel Pharmaceuticals AVDL Stock Holding History

Royal Bank of Canada’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,541
Closed -$227K – 7096
2025
Q4 		$227K Sell
10,541
-95,327
-90% -$1.85M ﹤0.01% 4681
2025
Q3 		$1.62M Sell
105,868
-22,500
-18% -$293K ﹤0.01% 3577
2025
Q2 		$1.14M Buy
128,368
+48,518
+61% +$426K ﹤0.01% 3789
2025
Q1 		$625K Sell
79,850
-3,541
-4% -$29.7K ﹤0.01% 3823
2024
Q4 		$876K Sell
83,391
-10,031
-11% -$122K ﹤0.01% 3661
2024
Q3 		$1.22M Sell
93,422
-5,934
-6% -$90.4K ﹤0.01% 3368
2024
Q2 		$1.4M Sell
99,356
-23,209
-19% -$378K ﹤0.01% 3185
2024
Q1 		$2.07M Buy
122,565
+118,990
+3,328% +$1.77M ﹤0.01% 2900
2023
Q4 		$50K Hold
3,575
– – ﹤0.01% 5990
2023
Q3 		$37K Sell
3,575
-8,885
-71% -$119K ﹤0.01% 5929
2023
Q2 		$205K Buy
+12,460
New +$162K ﹤0.01% 4722
2022
Q3 		– Sell
-200
Closed – – 7429
2022
Q2 		$0 Sell
200
-467
-70% -$1.92K ﹤0.01% 7359
2022
Q1 		$4K Sell
667
-77
-10% -$529 ﹤0.01% 7303
2021
Q4 		$7K Sell
744
-194
-21% -$1.77K ﹤0.01% 7140
2021
Q3 		$10K Buy
938
+517
+123% +$4.07K ﹤0.01% 6949
2021
Q2 		$2K Sell
421
-95
-18% -$754 ﹤0.01% 7235
2021
Q1 		$5K Sell
516
-353
-41% -$2.85K ﹤0.01% 7027
2020
Q4 		$6K Buy
+869
New +$5.43K ﹤0.01% 6570
2019
Q2 		– Sell
-1,000
Closed -$1K – 6853
2019
Q1 		$1K Buy
1,000
+750
+300% +$1.7K ﹤0.01% 6611
2018
Q4 		$1K Sell
250
-4,750
-95% -$16.2K ﹤0.01% 6543
2018
Q3 		$22K Sell
5,000
-532
-10% -$2.87K ﹤0.01% 5619
2018
Q2 		$34K Sell
5,532
-2,506
-31% -$17.6K ﹤0.01% 5314
2018
Q1 		$58K Buy
8,038
+2,009
+33% +$17.7K ﹤0.01% 4987
2017
Q4 		$49K Buy
6,029
+29
+0.5% +$272 ﹤0.01% 5184
2017
Q3 		$64K Hold
6,000
– – ﹤0.01% 5277
2017
Q2 		$66K Sell
6,000
-77
-1% -$773 ﹤0.01% 4979
2017
Q1 		$58K Buy
6,077
+77
+1% +$770 ﹤0.01% 5069
2016
Q4 		$62K Sell
6,000
-100
-2% -$1.1K ﹤0.01% 5132
2016
Q3 		$75K Sell
6,100
-110
-2% -$1.44K ﹤0.01% 4948
2016
Q2 		$67K Sell
6,210
-890
-13% -$9.49K ﹤0.01% 4971
2016
Q1 		$78K Hold
7,100
– – ﹤0.01% 4876
2015
Q4 		$86K Buy
7,100
+442
+7% +$6.89K ﹤0.01% 5012
2015
Q3 		$109K Sell
6,658
-1,942
-23% -$42.8K ﹤0.01% 4731
2015
Q2 		$182K Buy
8,600
+1,936
+29% +$34.7K ﹤0.01% 4439
2015
Q1 		$120K Buy
6,664
+48
+0.7% +$752 ﹤0.01% 4520
2014
Q4 		$113K Buy
6,616
+116
+2% +$1.66K ﹤0.01% 4663
2014
Q3 		$93K Buy
6,500
+500
+8% +$7.19K ﹤0.01% 4660
2014
Q2 		$90K Sell
6,000
-4,000
-40% -$48.2K ﹤0.01% 4593
2014
Q1 		$134K Buy
10,000
+4,000
+67% +$42.9K ﹤0.01% 4378
2013
Q4 		$48K Hold
6,000
– – ﹤0.01% 4907
2013
Q3 		$39K Hold
6,000
– – ﹤0.01% 4904
2013
Q2 		$37K Buy
+6,000
New +$31K ﹤0.01% 4803

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Royal Bank of Canada's AVDL Position: Q1 2026 in Review

Royal Bank of Canada sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 10,541 shares — an estimated $227K sold.

Royal Bank of Canada first reported a position in AVDL in Q2 2013 and held it in 42 quarters. The position peaked at $2.07M in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Royal Bank of Canada reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 10,541 Avadel Pharmaceuticals shares in Q1 2026, an estimated $227K.
  • Royal Bank of Canada first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 42 quarters.
  • Royal Bank of Canada's Avadel Pharmaceuticals position peaked at $2.07M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.